CN114939147A - Combined medicine for treating vascular plaque - Google Patents

Combined medicine for treating vascular plaque Download PDF

Info

Publication number
CN114939147A
CN114939147A CN202210259297.8A CN202210259297A CN114939147A CN 114939147 A CN114939147 A CN 114939147A CN 202210259297 A CN202210259297 A CN 202210259297A CN 114939147 A CN114939147 A CN 114939147A
Authority
CN
China
Prior art keywords
blood
parts
injection
citric acid
shenmai
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210259297.8A
Other languages
Chinese (zh)
Inventor
王炳彦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202210259297.8A priority Critical patent/CN114939147A/en
Publication of CN114939147A publication Critical patent/CN114939147A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A61K36/344—Codonopsis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/57—Magnoliaceae (Magnolia family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/79—Schisandraceae (Schisandra family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8968—Ophiopogon (Lilyturf)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a combined medicine for treating vascular plaque, which comprises the following components: composition for reducing homocysteine in blood, citric acid compound, folium Ginkgo extract injection, and SHENMAI injection or SHENMAI Chinese medicinal preparation. The invention has the beneficial effects that: compared with the traditional single medicine and operation treatment, the traditional Chinese and western medicine combined quadruple therapy has the remarkable characteristics of obvious efficiency, high cure rate, simple method, no wound, high safety, no toxic or side effect, short treatment course, low cost, easiness in popularization and the like. Has shown unique treatment effect in clinic and brings unexpected treatment effect for a plurality of patients with cardiovascular and cerebrovascular diseases.

Description

Combined medicine for treating vascular plaque
The technical field is as follows:
the invention relates to the technical field of medicines, and particularly relates to a combined medicine for treating vascular plaques.
Background art:
cardiovascular and cerebrovascular diseases are the leading factors threatening human health, the death rate accounts for more than 40% of the death rate of resident diseases, and the cardiovascular and cerebrovascular diseases represented by myocardial infarction and cerebral apoplexy are the first death factors of people in China, and are higher than tumors and other diseases.
In addition to high mortality, the high morbidity and disability rate of cardiovascular and cerebrovascular diseases places a heavy economic and psychological burden on society, families, and patient individuals. The traditional single-drug treatment has low significant efficiency, long treatment period, large trauma and high cost in surgical operation treatment, and the recovery of the function after healing is not ideal.
The invention content is as follows:
the invention provides a combined medicament for treating vascular plaques, which is used for solving the problems that the death rate of cardiovascular diseases is continuously increased in the prior art, and the traditional single medicament has low treatment efficiency and poor effect.
A combination for treating vascular plaque comprising: composition for reducing homocysteine in blood, citric acid compound, folium Ginkgo extract injection, and SHENMAI injection or SHENMAI Chinese medicinal preparation.
Preferably, the composition for reducing homocysteine in blood is a solid oral preparation, and the citric acid compound is a citric acid aqueous solution.
Preferably, the composition for reducing homocysteine in blood comprises: ginkgo biloba extract, folic acid, vitamin B6 and vitamin B12.
Preferably, the composition for reducing homocysteine in blood comprises, by weight, 48-160 parts of ginkgo biloba extract, 3.3-10 parts of folic acid, 6.7-20 parts of vitamin B6 and 0.017-0.05 part of vitamin B12.
Preferably, the aqueous citric acid solution comprises purified water and citric acid C 6 H 8 O 7 (ii) a Wherein the citric acid concentration is 0.305 mg/ml.
Preferably, the ginkgo biloba extract injection is mixed with ozone medical oxygen gas mixture, and the ratio of 1: 10 in normal saline, glucose solution or low molecular dextran.
Preferably, the Shenmai injection and the 5% glucose injection are diluted for use, and the ratio is 40-100: 500.
Preferably, the ginseng-ophiopogon root traditional Chinese medicine preparation comprises 1-2 parts of ginseng, 3.3-5 parts of astragalus, 3.3-5 parts of codonopsis pilosula, 3.3-5 parts of radix ophiopogonis, 1.7-3.3 parts of schisandra chinensis and 0.3-1 part of liquorice by weight.
Preferably 58.017g-190.05g of the composition for reducing homocysteine in blood, 305mg-915mg of the citric acid compound, 13mg-61.7mg of the ginkgo leaf extract in the ginkgo leaf extract injection and 6.67-33.33ml of the Shenmai injection or 13g-21.33g of the Shenmai Chinese medicinal preparation.
The beneficial effects of the invention include: compared with the traditional single medicine and operation treatment, the traditional Chinese and western medicine combined quadruple therapy has the remarkable characteristics of obvious efficiency, high cure rate, simple method, no wound, high safety, no toxic or side effect, short treatment course, low cost, easiness in popularization and the like. Has shown unique treatment effect in clinic and brings unexpected treatment effect for a plurality of patients with cardiovascular and cerebrovascular diseases.
The specific implementation mode is as follows:
in order to effectively reduce vascular plaque, comprehensively regulate a human body as a whole and more effectively adopt a dialectical treatment method, the embodiment of the invention provides a combined medicament for treating the vascular plaque, and the preferred embodiment of the invention is described below.
The cause of vascular occlusion has been recognized and understood by considerable scientific research in academia. It is generally believed that with age, blood vessels become increasingly constricted or even blocked by excessive lipid deposition on the vessel walls, which eventually leads to plaque fouling and atherosclerosis. Induce many kinds of heart and brain diseases, seriously endanger life and health.
The invention provides a combined medicine for treating vascular plaque, which comprises the following components: composition for reducing homocysteine in blood, citric acid compound, ginkgo leaf extract injection and ginseng and wheat injection or ginseng and wheat Chinese medicinal preparation.
Specifically, the four drugs have the best effect when used simultaneously, and a large amount of clinical and physical examination report data analysis for many years shows that the diseases such as coronary heart disease, myocardial infarction, cerebral apoplexy, cerebral hemorrhage, cerebral atrophy and the like are mainly caused by blockage of vascular plaques and microcirculation disturbance.
There are two important pathogenic association mechanisms for plaque formation:
on the one hand, lesions of the blood vessels themselves create the necessary conditions for the formation of plaques. Wherein high-concentration homocysteine in blood can roughen endothelial cells of blood vessels along with blood flow in blood circulation, so that an elastic layer and a collagen fiber layer of the blood vessel wall are damaged. Causing damage to vascular endothelium, disruption of the balance between fibrinolysis and coagulation, lipid metabolism and abnormal smooth muscle cell proliferation. Provides favorable conditions for the attachment formation of the plaque.
On the other hand, substances such as thrombocyte fibrinogen, blood sugar, triglyceride, cholesterol, etc. which are free in blood vessels are adhered together by calcium salt as an adhesive, and soft plaque, hard plaque, and mixed plaque are formed on blood vessels.
Over the years, plaques formed by calcium salt adhesion gradually deposit on the inner wall of a blood vessel damaged by high-concentration homocysteine to form blood vessel plaques, and gradually expand until various complications are caused and the health is endangered.
Therefore, the combined drug for treating the vascular plaque disclosed by the invention is mainly developed aiming at four key links of dialectical treatment aiming at the inducement of the vascular plaque, and has progressive and associated diagnosis and treatment effects, which are as follows: reducing the standard, eliminating, getting through and repairing.
Firstly, because high-concentration homocysteine can damage the inner wall of a blood vessel and provides a prerequisite for plaque attachment, the continuous damage of the high-concentration homocysteine to the inner wall of the blood vessel needs to be blocked firstly, and the continuous damage is mainly realized by orally taking a composition for reducing homocysteine in blood; compositions for reducing homocysteine include: the ginkgo biloba extract, the folic acid, the vitamin B6 and the vitamin B12 are all solid oral preparations. Wherein, the effective components of the ginkgo biloba extract in the combined medicine are 48mg to 160mg, the effective component of folic acid is 3.3mg to 10mg, the effective component of vitamin B6 is 6.7mg to 20mg, and the effective component of vitamin B12 is 17 mug to 50 mug.
The combined medicine can convert homocysteine with high index content in blood into glutathione and S-adenosylalanine which are necessary for human metabolism. Avoids the damage of high-concentration homocysteine to blood vessels and reduces the probability of the adhesion and formation of blood vessel plaques.
The composition has effects of resisting oxidation, scavenging free radicals, inhibiting lipid peroxidation of cell membrane, reducing lipid peroxidation, and improving SOD activity; can inhibit platelet aggregation and prevent thrombosis; has protective effect on cardiac dysfunction caused by myocardial ischemia; improving blood circulation and cell metabolism of brain tissue; improve blood rheological property, reduce blood viscosity, and enhance erythrocyte deformability.
Secondly, substances such as platelet fibrinogen, blood sugar, triglyceride, cholesterol and the like which are dissociated in the blood vessel are adhered together by using a calcium salt as an adhesive, and plaques are formed on the blood vessel; therefore, calcium salts deposited in various organs and vascular plaques in vivo are digested by citric acid compounds, and insoluble calcium carbonate is converted into soluble calcium chloride, so that the plaques are disintegrated, and the purpose of decomposing the plaques is achieved; the citric acid compound is citric acid aqueous solution, and citric acid with concentration more than 95.5% which meets the GB 1886.235-2016 standard is blended with purified water according to a certain proportion; wherein the citric acid concentration content is 0.305 mg/ml. The effective content of citric acid in the combination drug is 305mg-915 mg.
Thirdly, intravenous injection of plant extract medicine and addition of blue oxygen therapy are adopted to improve the blood oxygen content of the organism, enhance the metabolic capability of the organism and dredge the blood vessels. Through medicine, oxygen therapy and other methods, the medicine has the functions of promoting blood circulation to disperse blood clots, lowering the concentration of platelet fibrinogen, blood sugar, triglyceride, cholesterol and other matter in blood vessel related to blood hypercoagulability and plaque formation. The plant extract medicine is folium Ginkgo extract, wherein the effective component of folium Ginkgo extract is 13mg-61.7mg, and the content of ginkgetin glycoside is 3.16mg-15 mg. The ginkgo biloba extract has the best effect in an intravenous injection mode, ozone medical oxygen mixed gas can be added into the ginkgo biloba extract injection, and the ratio of the ozone medical oxygen mixed gas to the ozone medical oxygen mixed gas is 1: 10 in normal saline, glucose solution or low molecular dextran. It is mainly used for peripheral circulatory disturbance such as peripheral arterial occlusive disease, intermittent claudication, paralysis and coldness of hands and feet, and soreness of limbs, acute and chronic brain insufficiency such as apoplexy, inattention, memory deterioration, dementia, etc., and sequela thereof. The medical ozone oxygen mixed gas can improve hemorheology, raise basophilic granulocyte of blood, reduce aggregability of erythrocyte, reverse the state of vascular wall, reduce platelet aggregability, reduce blood viscosity, soften vascular wall, resolve thrombus and make blood flow smoother, thereby fundamentally reversing cardiovascular and cerebrovascular diseases.
Finally, the smooth muscle cells and the fibrous matrix of the vascular wall are gradually repaired in a mode of injecting plant extract medicines or oral Chinese medicinal preparations through veins. The health state of blood and microcirculation of the body is maintained, and a good internal environment is provided for various functional tissues of the body to deliver nutrient substances and metabolize harmful substances. Reach a dynamic nutrition balance state and avoid the recurrence of cardiovascular diseases.
The Shenmai injection is diluted with 5% glucose injection at a ratio of 40-100: 500. The preparation has effects of invigorating qi, relieving depletion, nourishing yin, promoting fluid production, and promoting pulse. Can be used for treating coronary heart disease and chronic pulmonary heart disease. Can improve immunity of patients.
The Shenmai Chinese medicinal preparation comprises 1 to 2 portions of ginseng, 3.3 to 5 portions of astragalus, 3.3 to 5 portions of radix codonopsitis, 3.3 to 5 portions of dwarf lilyturf tuber, 1.7 to 3.3 portions of Chinese magnoliavine fruit and 0.3 to 1 portion of liquorice according to the weight portion. In the formula, ginseng is used as monarch, radix ophiopogonis is used as minister, schisandra chinensis is used as adjuvant, and liquorice is used as dispatcher. The prescription can be used for treating myocardial infarction and angina pectoris, regulating blood pressure, resisting arrhythmia, inflammation, cor pulmonale, shock, improving liver function, and resisting mutation. Can protect myocardial cells, enhance immunity, improve microcirculation and cardiac function, increase coronary blood flow, resist myocardial ischemia, regulate myocardial metabolism, and reduce oxygen consumption.
The combined medicine for treating the vascular plaque comprises 58.017-190.05 g of a composition for reducing homocysteine in blood, 305-915 mg of a citric acid compound, 13-61.7 mg of a ginkgo leaf extract in a ginkgo leaf extract injection and 6.67-33.33ml of a Shenmai injection or 13-21.33 g of a Shenmai traditional Chinese medicine preparation. According to the disease condition, the dosage is usually three times a day, and 15-25 days are a course of treatment. Through four aspects of reducing the blood standard, eliminating, getting through and repairing, getting through blood circulation and microcirculation, solving various diseases caused by blood circulation disorder caused by blockage.
In the combined medicine for treating vascular plaque in the embodiment of the invention, the ginkgo leaf extract injection and the Shenmai injection are preferably in an intravenous injection form, and the other parts are taken orally as a composition, or all the parts can be taken orally as a composition.
The effects achieved by the combination provided by the invention are described in detail below in connection with animal tests and clinical results.
A composition for reducing homocysteine comprising: ginkgo biloba extract, folic acid, vitamin B6 and vitamin B12. Through detection of the Western-Ans Union quality detection technology, Inc., the combined medicaments pass an acute oral toxicity test, a test animal is a mouse, the animal is uniformly mixed by expanding 100 times according to the proportion of the formula, 2.5g of the combined medicaments are weighed and added into 20mL of pure water, and the mixture is uniformly mixed. 20 mice with the weight of 18 g-22 g are taken, the male and the female are respectively half, the maximum dosage method is adopted, oral gavage is carried out, the continuous observation is carried out for 14 days, no toxic symptom and death condition are seen, the animals are sacrificed after the observation period and are subjected to autopsy, and no abnormality is found in organs and tissues.
Similarly, the ginseng and ophiopogon root traditional Chinese medicine preparation passes the acute oral toxicity test in the way.
Unique treatment effects are also achieved clinically, and the following are some effective cases of "carotid plaque":
table 1: sex-age table for effective cases
Figure BDA0003549470400000061
Figure BDA0003549470400000071
Table 2: table 1 comparison of examination results before and after treatment for some patients
Figure BDA0003549470400000072
Figure BDA0003549470400000081
Figure BDA0003549470400000091
In conclusion, the size of the vascular plaque is reduced after 15-25 days as a treatment course, a remarkable and unique treatment effect is achieved, the hope of reducing or curing the disease condition is brought to a plurality of patients with cardiovascular and cerebrovascular diseases, and the problem of irreversible vascular plaque is solved by combining Chinese and western medicines from the root.
It will be apparent to those skilled in the art that various changes and modifications may be made in the present invention without departing from the spirit and scope of the invention. Thus, if such modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include such modifications and variations.

Claims (9)

1. A combination for treating vascular plaque, comprising: composition for reducing homocysteine in blood, citric acid compound, folium Ginkgo extract injection, and SHENMAI injection or SHENMAI Chinese medicinal preparation.
2. The combination according to claim 1, for treating vascular plaques, wherein: the composition for reducing homocysteine in blood is a solid oral preparation, and the citric acid compound is a citric acid aqueous solution.
3. The combination according to claim 1, wherein the composition for reducing homocysteine in the blood comprises: ginkgo biloba extract, folic acid, vitamin B6 and vitamin B12.
4. The combination drug for treating vascular plaque according to claim 3, wherein said composition for reducing homocysteine in blood comprises 48-160 parts by weight of ginkgo biloba extract, 3.3-10 parts by weight of folic acid, 6.7-20 parts by weight of vitamin B6 and 0.017-0.05 parts by weight of vitamin B12.
5. The combination according to claim 2, for treating vascular plaques, wherein: the citric acid aqueous solution comprises purified water and citric acid C 6 H 8 O 7 (ii) a Wherein the citric acid concentration content is 0.305 mg/ml.
6. The combination according to claim 1, for the treatment of vascular plaques characterized in that: the ginkgo leaf extract injection is mixed with ozone medical oxygen gas mixture, and the ratio of ozone medical oxygen gas mixture to ozone medical oxygen gas mixture is 1: 10 in normal saline, glucose solution or low molecular dextran.
7. The combination according to claim 1, for the treatment of vascular plaques characterized in that: the Shenmai injection is diluted with 5% glucose injection at a ratio of 40-100: 500.
8. The combination according to claim 1, for the treatment of vascular plaques characterized in that: the Shenmai Chinese medicinal preparation comprises 1 to 2 parts of ginseng, 3.3 to 5 parts of astragalus, 3.3 to 5 parts of codonopsis pilosula, 3.3 to 5 parts of dwarf lilyturf tuber, 1.7 to 3.3 parts of Chinese magnoliavine fruit and 0.3 to 1 part of liquorice by weight.
9. The combination according to claim 1, for the treatment of vascular plaques characterized in that: the composition for reducing homocysteine in blood is 58.017g-190.05g, the citric acid compound is 305mg-915mg, the ginkgo leaf extract in the ginkgo leaf extract injection is 13mg-61.7mg, and the Shenmai injection is 6.67-33.33ml or the Shenmai Chinese medicinal preparation is 13g-21.33 g.
CN202210259297.8A 2022-03-16 2022-03-16 Combined medicine for treating vascular plaque Pending CN114939147A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210259297.8A CN114939147A (en) 2022-03-16 2022-03-16 Combined medicine for treating vascular plaque

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210259297.8A CN114939147A (en) 2022-03-16 2022-03-16 Combined medicine for treating vascular plaque

Publications (1)

Publication Number Publication Date
CN114939147A true CN114939147A (en) 2022-08-26

Family

ID=82905993

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210259297.8A Pending CN114939147A (en) 2022-03-16 2022-03-16 Combined medicine for treating vascular plaque

Country Status (1)

Country Link
CN (1) CN114939147A (en)

Similar Documents

Publication Publication Date Title
Copeland III et al. Intravenous hyperalimentation as an adjunct to cancer chemotherapy
WO2016015391A1 (en) Pharmaceutical composition for treating cardiovascular or cerebrovascular diseases and preparation method therefor
CN1197481C (en) Method for treatment of chronic venous insufficiencies using extract of red vine leaves
CN103230478A (en) Selenium-rich natto product
CN114939147A (en) Combined medicine for treating vascular plaque
CN107648512A (en) A kind of Chinese medicine composition and preparation method for improving microcirculation in human body
CN106729675A (en) It is a kind of to treat pharmaceutical composition of cardiovascular and cerebrovascular disease and preparation method thereof
CN1817354A (en) Injection of manchurian wildginge and astragalus root and its preparing method
CN112807292B (en) Application of bunge auriculate root benzophenone in preparation of uric acid reducing medicines
CN101879272A (en) Chinese medicinal compound for treating coronary heart diseases, preparation method and application thereof
CN104147053A (en) Oral liquid of traditional Uygur medicine named Kulumuti, and preparation method thereof
Taiwo et al. Cardiovascular effects of Vernonia amygdalina in rats and the implications for treatment of hypertension in diabetes
CN102579688B (en) Blood pressure reducing chrysanthemum and dogbane leaf traditional Chinese medicine preparation
CN110935002A (en) Composition with blood pressure lowering effect and application thereof
CN109771414B (en) Pharmaceutical composition for treating hemorrhagic shock
CN101632783B (en) Application of Chinese medicinal composition in preparing medicament for treating cor pulmonale
CN104288262A (en) Method for preparing altitude stress resistant medicament
CN100384439C (en) Medicinal composition for treating and/or preventing heart brnin blood vessel disease and its preparation method
CN1225542C (en) Health care medicinal liquor
CN106344634A (en) Mango peel extract and preparation method and application thereof
CN1507906A (en) Medicine for treating cardio-cerebro vascular disease and preparing method thereof
CN111068004A (en) Traditional Chinese medicine composition for reducing blood pressure and regulating blood fat
CN117461835A (en) Dietary therapy formula suitable for tonifying kidney, lumbocrural pain, dredging heart and cerebral vessels and preventing and resisting cancer
CN110694030A (en) Composition for preventing and treating diabetic neuropathy
CN111437339A (en) Cortex lycii radicis blood pressure reducing formula

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication